摘要
目的:探讨D2-40标记人乳腺癌组织微淋巴管密度(LMVD)的可行性及其临床病理意义。方法:采用免疫组织化学SABC法检测50例乳腺癌和15例乳腺良性病变组织中D2-40的表达,观察其染色情况并计数D2-40阳性微淋巴管,分析其与乳腺癌病理参数的关系。结果:乳腺癌组织中的LMVD高于良性病变组(P<0.01),肿瘤边缘区LMVD均值显著高于肿瘤中心区(P<0.01);肿瘤边缘区LMVD与乳腺癌的肿瘤大小、临床分期及淋巴结转移状态相关(P<0.05),与年龄、组织学分型、ER、PR及Her-2受体状态无关(P>0.05);中心区LMVD与上述临床病理参数均无明显相关(P>0.05)。结论:D2-40可以特异性识别人乳腺癌组织中微淋巴管内皮细胞,其标记的微淋巴管主要分布于癌周组织;LMVD与乳腺癌的肿瘤大小、临床分期及淋巴结转移状态密切相关,可用来评估乳腺癌淋巴转移风险。
Objective To investigate the feasibility of D2-40 for the detection of Lymphatic Microvessel Density and the correlation with its clinicopathological factors in breast cancer. Methods Making use of immunohistochemistry to research the expression of D2-40 in 50 cases of breast cancer and 10 cases of benigh breast tumor, which Lymphatic Microvessel Density was counted,and analysis the correlation with its clinicopathological factors. Results The LMVD in breast cancer was significant higher than that in the benigh lesion （P 〈 0.01 ） and the LMVD in tumor borderline was higher than that in tumor center tissues （P 〈 0.01 ）. The LMVD in the borderline had positive relation to the tumor size, clinical stage and lymph node metastasis （P 〈 0.01）, but it had no significant difference from age, histologic types, HER2-status, progestoger and estrogen receptor condition （P 〉 0.05）, whereas, There was no significant correlation between the LMVD in tumor center tissues and any clinicopathological factors. Conclusions the new monoclonal antibody D2-40 can specifically recognition the lymphatic endothelial ceils in human breast cancer tissue. The lymphatic microvessel, D2-40 marked, mainly distributes in the tumor borderline, and the LMVD in peritumoral correlated significantly with tumor size, clinical stage and lymph node metastasis, which may assess the risk of lymph node metastasis in breast cancer.
出处
《实用医学杂志》
CAS
北大核心
2009年第18期3051-3053,共3页
The Journal of Practical Medicine
